US
CA
NZ
UK
AU
IND
Last update at 2025-06-13T16:36:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Trump Trade: Trump considers 50% tariff on EU, 25% on iPhones
Sat 24 May 25, 02:15 PMBayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases
Fri 23 May 25, 02:01 PMOTC Markets Group Welcomes Bayer AG to OTCQX
Fri 23 May 25, 11:00 AMBayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation
Wed 21 May 25, 04:33 PMThe Zacks Analyst Blog Highlights Bayer, Novo Nordisk, GSK, Merck and AbbVie
Mon 19 May 25, 01:51 PMPharma Stock Roundup: BAYRY Q1 Earnings, NVO & GSK's New Deals
Fri 16 May 25, 12:06 PMBayer Q1 Earnings Beat Estimates, Crop Science Unit Hurts Sales
Tue 13 May 25, 01:56 PMStocks to watch next week: Alibaba, Walmart, Burberry, Imperial Brands and Tui
Fri 09 May 25, 01:07 PMBayer to exit US seed treatment equipment business, email says
Wed 30 Apr 25, 11:13 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 4670.00M | 2046.00M | -17250.00000M | 2880.00M | 2318.00M |
| Minority interest | -16.00000M | -22.00000M | 175.00M | 180.00M | 171.00M |
| Net income | 4150.00M | 1000.00M | -10495.00000M | 4091.00M | 1695.00M |
| Selling general administrative | 16922.00M | 15325.00M | 15932.00M | 16164.00M | 15479.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 30868.00M | 27265.00M | 22262.00M | 26078.00M | 22576.00M |
| Reconciled depreciation | 6503.00M | 3056.00M | 13259.00M | 5365.00M | 6352.00M |
| Ebit | 9121.00M | 7475.00M | 6972.00M | 6980.00M | 4257.00M |
| Ebitda | 13030.00M | 6449.00M | -2395.00000M | 10093.00M | 10285.00M |
| Depreciation and amortization | - | - | - | - | - |
| Non operating income net other | - | - | - | - | 0.00000M |
| Operating income | 7333.00M | 6909.00M | -714.00000M | 4532.00M | 323.00M |
| Other operating expenses | 528.00M | -296.00000M | -69.00000M | 59.00M | 1477.00M |
| Interest expense | 1857.00M | 1347.00M | 1596.00M | 1848.00M | 1615.00M |
| Tax provision | 504.00M | 1024.00M | -1689.00000M | 450.00M | 607.00M |
| Interest income | 379.00M | 346.00M | 202.00M | 294.00M | 321.00M |
| Net interest income | -1823.00000M | -945.00000M | -1271.00000M | -1499.00000M | -1265.00000M |
| Extraordinary items | - | - | - | - | 0.00000M |
| Non recurring | - | - | - | - | 0.00000M |
| Other items | - | - | - | - | 0.00000M |
| Income tax expense | 504.00M | 1024.00M | -1689.00000M | 443.00M | 496.00M |
| Total revenue | 50739.00M | 44081.00M | 41400.00M | 43545.00M | 39586.00M |
| Total operating expenses | 43406.00M | 37172.00M | 42114.00M | 39013.00M | 39263.00M |
| Cost of revenue | 19871.00M | 16816.00M | 19138.00M | 17467.00M | 17010.00M |
| Total other income expense net | - | - | - | -3852.00000M | -2371.00000M |
| Discontinued operations | - | - | 5074.00M | 1700.00M | 321.00M |
| Net income from continuing ops | 4166.00M | 1022.00M | -15561.00000M | 2430.00M | 1711.00M |
| Net income applicable to common shares | 4150.00M | 1000.00M | -10495.00000M | 4091.00M | 1695.00M |
| Preferred stock and other adjustments | - | - | - | - | 0.00000M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 116259.00M | 124877.00M | 120241.00M | 117046.00M | 126258.00M |
| Intangible assets | 23363.00M | 24183.00M | 26258.00M | 26029.00M | 34709.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | 521.00M | 545.00M | 674.00M | 1534.00M |
| Total liab | 83181.00M | 85951.00M | 87073.00M | 86347.00M | 78741.00M |
| Total stockholder equity | 32927.00M | 38773.00M | 33020.00M | 30524.00M | 47337.00M |
| Deferred long term liab | - | 3797.00M | 4312.00M | 4383.00M | 5517.00M |
| Other current liab | 567.00M | 16105.00M | 17097.00M | 21306.00M | 13329.00M |
| Common stock | - | 2515.00M | 2515.00M | 2515.00M | 2515.00M |
| Capital stock | 2515.00M | 2515.00M | 2515.00M | 2515.00M | 2515.00M |
| Retained earnings | - | 17233.00M | 13345.00M | 13057.00M | 26151.00M |
| Other liab | - | 17076.00M | 21189.00M | 16160.00M | 18614.00M |
| Good will | 32299.00M | 39648.00M | 40106.00M | 36080.00M | 39126.00M |
| Other assets | - | 10481.00M | 10299.00M | 9920.00M | 10742.00M |
| Cash | 5907.00M | 5171.00M | 4564.00M | 4191.00M | 3185.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 29457.00M | 35084.00M | 29403.00M | 36768.00M | 23215.00M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | 35729.00M | 34915.00M | 33802.00M | 36225.00M | 34446.00M |
| Short term debt | - | - | - | - | 1676.00M |
| Short long term debt | 4410.00M | 7257.00M | 2817.00M | 8148.00M | 1676.00M |
| Short long term debt total | - | - | - | - | - |
| Other stockholder equity | - | 19025.00M | 17160.00M | 14951.00M | 18587.00M |
| Property plant equipment | - | 13674.00M | 12688.00M | 11723.00M | 12479.00M |
| Total current assets | 37556.00M | 37760.00M | 32578.00M | 35675.00M | 32439.00M |
| Long term investments | - | - | - | - | 1984.00M |
| Net tangible assets | - | -21294.00000M | -29044.00000M | -26965.00000M | -21277.00000M |
| Short term investments | 4680.00M | 4982.00M | 3175.00M | 7692.00M | 2219.00M |
| Net receivables | 9343.00M | 13450.00M | 12980.00M | 12157.00M | 14851.00M |
| Long term debt | 37226.00M | 32829.00M | 35549.00M | 32268.00M | 35955.00M |
| Inventory | 13929.00M | 13636.00M | 11314.00M | 10961.00M | 10650.00M |
| Accounts payable | 7456.00M | 7545.00M | 6792.00M | 5678.00M | 6426.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | - | - | - | 93699.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 78703.00M | 87117.00M | 87663.00M | 81386.00M | 93699.00M |
| Capital lease obligations | 1238.00M | 1234.00M | 1165.00M | 1137.00M | 1251.00M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -2978.00000M | 4302.00M | -4027.00000M | -575.00000M | 5717.00M |
| Change to liabilities | 612.00M | 854.00M | -347.00000M | 759.00M | 257.00M |
| Total cashflows from investing activities | -2381.00000M | 855.00M | -4073.00000M | -671.00000M | -34152.00000M |
| Net borrowings | -974.00000M | -2452.00000M | 4467.00M | -4296.00000M | 17819.00M |
| Total cash from financing activities | -4220.00000M | -5645.00000M | 423.00M | -8389.00000M | 23432.00M |
| Change to operating activities | -1407.00000M | 436.00M | 9220.00M | 786.00M | 704.00M |
| Net income | 4150.00M | 1000.00M | -10495.00000M | 4091.00M | 1695.00M |
| Change in cash | 607.00M | 373.00M | 1006.00M | -867.00000M | -3383.00000M |
| Begin period cash flow | 4564.00M | 4191.00M | 3185.00M | 4052.00M | 7435.00M |
| End period cash flow | 5171.00M | 4564.00M | 4191.00M | 3185.00M | 4052.00M |
| Total cash from operating activities | 7093.00M | 5089.00M | 4903.00M | 8207.00M | 7917.00M |
| Issuance of capital stock | - | - | - | 0.00000M | 8986.00M |
| Depreciation | 3949.00M | 3740.00M | 3444.00M | 4214.00M | 2888.00M |
| Other cashflows from investing activities | 218.00M | 137.00M | 134.00M | 135.00M | 247.00M |
| Dividends paid | -1985.00000M | -1993.00000M | -2751.00000M | -2611.00000M | 2402.00M |
| Change to inventory | -2170.00000M | -173.00000M | -900.00000M | -103.00000M | 636.00M |
| Change to account receivables | 269.00M | -61.00000M | 695.00M | 14.00M | 2520.00M |
| Sale purchase of stock | - | - | - | - | 0.00000M |
| Other cashflows from financing activities | -1251.00000M | -1200.00000M | -1293.00000M | -1482.00000M | -971.00000M |
| Change to netincome | 1690.00M | -707.00000M | 3286.00M | -1554.00000M | -783.00000M |
| Capital expenditures | 2949.00M | 2611.00M | 2418.00M | 2650.00M | 2593.00M |
| Change receivables | - | - | - | - | 0.00000M |
| Cash flows other operating | - | - | - | - | 0.00000M |
| Exchange rate changes | - | - | - | - | 0.00000M |
| Cash and cash equivalents changes | - | - | - | - | 0.00000M |
| Change in working capital | -2696.00000M | 1056.00M | 8668.00M | 1456.00M | 4041.00M |
| Stock based compensation | - | - | - | - | - |
| Other non cash items | 2342.00M | 1307.00M | 1081.00M | 1309.00M | 1596.00M |
| Free cash flow | 4144.00M | 2478.00M | 2485.00M | 5557.00M | 5324.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BAYZF Bayer AG |
-0.76 2.36% | 31.50 | - | 1.51 | 0.45 | 0.64 | 1.11 | 5.55 |
| LLY Eli Lilly and Company |
11.51 1.42% | 823.54 | 78.14 | 31.95 | 16.34 | 45.83 | 16.65 | 54.36 |
| JNJ Johnson & Johnson |
1.01 0.64% | 157.67 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| ABBV AbbVie Inc |
- -% | 192.42 | 61.52 | 14.86 | 5.62 | 51.62 | 6.76 | 20.58 |
| MRK Merck & Company Inc |
0.42 0.51% | 82.24 | 59.83 | 12.33 | 4.50 | 6.47 | 4.94 | 23.79 |
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.
Kaiser-Wilhelm-Allee 1, Leverkusen, Germany, 51368
| Name | Title | Year Born |
|---|---|---|
| Mr. Werner Baumann | Chairman of Management Board, CEO & Chief Sustainability Officer | 1962 |
| Mr. Wolfgang U. Nickl | CFO & Member of Management Board | 1969 |
| Mr. Heiko W. J. Schipper | Member of Management Board & Pres of the Consumer Health Division | 1969 |
| Mr. Stefan Oelrich | Head of the Pharmaceuticals Division & Member of the Board of Management | 1968 |
| Ms. Sarena S. Lin | Chief Transformation & Talent Officer, Labor Director and Member of Management Board | 1971 |
| Mr. Rodrigo Santos | Member of Management Board & Pres of the Crop Science Division | 1973 |
| Mr. Bernd-Peter Bier | Head of Accounting and Head of Taxes | 1967 |
| Mr. Oliver Maier | Head of Investor Relations | NA |
| Dr. Gabriel Harnier | Head of Law, Patents & Compliance | 1971 |
| Mr. Michael Preuss | Head of Communications, Gov. Relations and Corp. Brand | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...